TF Market Research



Title:

DAEWOONG PHARMACEUTICAL CO. LTD.-COMPANY INSIGHT

Price:$960.00
Publication Date:Jul 14, 2008
Source:LIFE SCIENCE ANALYTICS
Author:HARINATHA, G.
Brief Excerpt:...Daewoong Pharmaceutical Co. Ltd is a manufacturer engaged in the provision of pharmaceutical products. The company was founded in #### with a mission to provide treatment and sa tisfaction to patients and families with high quality drugs. Its vision is to be a global healthcare group leading improvement in the quality of life. Daewoong's core technology offers Wound Healing-EGF (Epidermal Growth Factor) stimulating the entire woun d healing process, biopharmaceuticals-e fficient manufacturing system utilizing animal cells, microbes and viral vectors, new pharmac euticals-excellent antibody screening and edymetox systems, formulation and drug delivery system-susta ined release of peptides; stabilization of moisture- sensitive molecules by using double layer/core tablet s and chemical synthesis- synthesizing and purifying techniques produce value-added products. Daewoong offers products in four categories which include: Biopharmaceutical, New Chemical Entity (NCE), Drug...
Length:25 Pages (24 Billable Pages)
Company:DAEWOONG PHARMACEUTICAL CO LTD
Geographic Regions:ASIA, EASTERN ASIA, KOREA, REPUBLIC OF
Non-Billable Page Numbers:2
Format:Adobe Acrobat Adobe Acrobat

Sections
TitleStarting PageNumber of Pages
Company Information11
Daewoong Pharmaceutical Co. Ltd. [NonUS -- Symbol : Stock Code Number : 069620 (KOE)]11
Formation Date: 194511
Business Summary11
Product Glance31
Trial Phase31
No of Products32
Diseasehub Classification31
Disease Hub41
Product Summary41
Trial Phase Source Partner42
Condition Treated51
Products51
Product Details51
1. Perivar Disease Hub Description51
Therapeutic Indication Current Trial Trial Details Last Updated51
2. Smecta Disease Hub Description61
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 3. Erdos Disease Hub Description61
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 4. Tiropa Disease Hub Description61
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 5. Asacol Disease Hub Description61
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 6. Gasmotin Disease Hub Description61
Therapeutic Indication Current Trial Trial Details61
Last Updated Partnering Details71
7. Tenstaten Disease Hub Description71
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 8. Dynacirc SRO Disease Hub Description71
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 9. Olmetec Disease Hub Description71
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 10. Methycobal Disease Hub Description71
Therapeutic Indication Current Trial Trial Details Last Updated 11. Gluriad Disease Hub Description81
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 12. Diabex Disease Hub Description81
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 13. Airtal Disease Hub Description81
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 14. Fenopron Disease Hub Description81
Therapeutic Indication Current Trial Trial Details Last Updated 15. Rize Disease Hub Description81
Therapeutic Indication Current Trial Trial Details Last Updated 16. Gliatilin Disease Hub Description91
Therapeutic Indication Current Trial Trial Details Last Updated 17. Chicclean Disease Hub Description91
Therapeutic Indication Current Trial Trial Details Last Updated 18. Chicclean Disease Hub Description91
Therapeutic Indication Current Trial Trial Details Last Updated 19. Easyef Disease Hub Description91
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 20. Asacol Disease Hub Description91
Therapeutic Indication Current Trial Trial Details91
Last Updated Partnering Details102
21. Olmetec Plus Disease Hub Description101
Therapeutic Indication Drug Class Current Trial Trial Details101
Last Updated 22. Lipice Disease Hub Description101
Therapeutic Indication Current Trial Trial Details Last Updated 24. Botox Disease Hub Description101
Therapeutic Indication Current Trial Trial Details Last Updated 25. Nicostop Disease Hub Description101
Therapeutic Indication Drug Class101
Current Trial Trial Details111
Last Updated 26. Levulan PDT Disease Hub Description111
Therapeutic Indication Current Trial Trial Details111
27. Allelock Disease Hub Description111
Therapeutic Indication111
Current Trial Trial Details Last Updated 28. Ursa Disease Hub Description121
Therapeutic Indication Liver Current Trial M Trial Details Last Updated 29. Ursa complex Disease Hub Description Ursa121
Therapeutic Indication Current Trial Trial Details Last Updated 30. Plunazol Disease Hub Description121
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 31. Caretropin Disease Hub Description121
Therapeutic Indication Growth Drug Class Hormone Current Trial PA Trial Details Presently it Last Updated 5/14/2008 32. rh-EP121
Therapeutic Indication Drug Class Current Trial121
Trial Details Presently it is Last Updated 5/17/2008 33. Catrix wound dressing Disease Hub Dermatology Description Catrix Wou131
Therapeutic Indication Current Trial Trial Details131
Last Updated Partnering Details131
34. Easyef Disease Hub Description131
Therapeutic Indication Current Trial Trial Details Last Updated 35. Easyef Disease Hub Description131
Therapeutic Indication Mucositis Current Trial II Trial Details Presently it is in Last Updated 5/17/2008 36. Tamsulosin SR D131
Therapeutic Indication Benign Prostatic Current Trial I Trial Details Presently it is in Last Updated 5/15/2008 37. Doxazosin141
Therapeutic Indication Current Trial Trial Details Last Updated 41. DWP418 Disease Hub Description141
Therapeutic Indication Multiple Sclerosis Current Trial PC Trial Details Presently it is in Last Updated 5/11/2008 46. Phense151
Therapeutic Indication Drug Class Current Trial Trial Details153
Last Updated Partnering Details181
47. Easyef Disease Hub Description181
Therapeutic Indication Current Trial Trial Details Last Updated 48. Easyef Disease Hub Description191
Therapeutic Indication Current Trial Trial Details Last Updated 49. DWP423 Disease Hub Description191
Therapeutic Indication Infectious Current Trial NA Trial Details Presently it Last Updated 4/3/2007 50. DWP-404 / DWP40458 Di191
Therapeutic Indication Current Trial Trial Details191
Last Updated191
Corporate Partners201
Deal Category: Product Date Source201
Partner202
Management Profile221
Yoon, Yeong Hwan -- Chairman221
Yoon, Jae Seung -- Vice Chairman and Chief Executive Officer221
Lee, Jong Wook -- Chief Executive Officer221
Koh, Yea-Wook -- General manager, R&D Center221
Choi, Soo Jin -- General Manager, R&D Center221
Park, Jae Hong -- Managing Director221
2/11/2008 -- Daewoong Pharmaceutical, selected as a distinguished company of favorable labor- management relations231
10/6/2005 -- The Health and Welfare Committee Of The National Assembly Visited Daewoong Pharmaceutical Hyangnam Factory231
9/21/2005 -- Making High Quality Drug-'Differentiated Purchasing System'231
9/2/2005 -- Success Story Of Coenzyme Q10 Development231
5/6/2005 -- Easyef (Ingredient: EGF) With Excellent Effect Upon Treatment Of Chronic Injury And Scar Inhibition231
3/29/2005 -- Daewoong Pharmaceutical Implements SRM System As Strategic Advanced Purchase Infra231
9/21/2004 -- New Concept Anti-wrinkle Cosmetics Containing EGF Was Approved231
8/31/2005 -- Joint Research On Alternative Medicine To Therapeutic Antibodies With Scotch Haptogen241
5/16/2005 -- Haptogen Announce Landmark Collaboration with DaeWoong Pharmaceuticals to Develop Novel Anti-infectives241
3/25/2005 -- New And Excellent ARB Hypertension Therapy "Olmetec Plus" Was Released241
12/22/2004 -- Lescarden Enters Into Distribution Agreement for Catrix Wound Dressing in Korea241
1/23/2003 -- Tillotts Pharma License Out the Rights of Asacol in South-Korea241
5/10/1999 -- Dainippon Licenses Gasmotin to Daewoong of South Korea241
2/1/1992 -- Allelix Supplies Epidermal Growth Factor to Daewoong241
Intellectual Property251
12/11/2006 -- Moxicle Patented Core Tablet Manufacturing Technology251
8/24/2004 -- Obtained Patent Related With Development Of Platelet Therapy251
Product Update251
5/15/2007 -- Eisai Submits Application for Gastroprokinetic Agent Gasmotin in Thailand251
Regulatory251
10/3/2007 -- DUSA's Levulan Kerastick Receives Marketing Approval in Korea251
Tables
TitleStarting PageNumber of Pages
of Contents21

Enter the keyword(s) which you would like to search for within this document and click "Search"

 
Purchase Report
Price: $960.00

Looking For Something Else?





TF Market Research

TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.

  about us | contact us | public company index | private company index | pcan | widget | your privacy rights | terms & conditions  

Copyright © 2008 Alacra, Inc., 100 Broadway, Suite 1100, New York, NY 10005. All rights reserved.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.